Graft engineering in autologous and allogeneic HSC transplantation

While HSCT is a well-founded therapeutic option for the treatment of a variety of hematologic malignancies and non-malignant diseases, it is also associated with severe side effects. The CliniMACS® Cell Separation System offers a variety of tools that enables the removal of T cells, T cells subsets, B cells, and other unwanted cells from hematopoietic stem cell grafts to overcome relapse and side effects like graft-versus-host disease. Different clinical strategies are being evaluated to engineer stem cell grafts for different purposes based on Miltenyi Biotec's cell separation technologies and clinical grade antibodies for different epitopes.

For complete regulatory notices click here.